Recommended

GSK appoints new CEO
New webinar | Addressing the time-to-result challenge posed by short shelf-life radiopharmaceuticals, register today
Genmab acquires biotech Merus for $8bn
US FDA licensing first for IL-23 inhibitor to treat paediatric psoriasis
Teva makes progress on API business divestment
Takeda to move away from cell therapy
Whitepapers/App Notes/Posters

Whitepaper: The performance of PROSOLV® EASYtab SP in four medium-dose

14
SHARES

Posted: 5 April 2019 | | No comments yet

In the present study, the performance of PROSOLV® EASYtab SP was tested in four DC formulations with different model APIs. Each of the selected APIs presented a particular challenge in terms of producing tablets with suitable hardness, weight, uniformity, content uniformity and/or reliable dissolution profiles.

PROSOLV® EASYtab SP was shown to perform considerably better than the corresponding physical mixture of its components for all formulations tested.

    To read this whitepaper in full, please complete the form below. By clicking submit you confirm that you accept our terms and conditions and privacy policy.


    *


    *


    *


    *


    *


    *


    *


    *

    This content is provided to you for free thanks to the kind support of our sponsors: JRS Pharma

    Share via
    Share via